Evidence map›Paper›PMID 28458699›Full record

ArticleARYA atherosclerosis2016

Pentoxifylline and prevention of contrast-induced nephropathy: Is it efficient in patients with myocardial infarction undergoing coronary angioplasty?

Ali Eshraghi, Roya Naranji-Sani, Hourak Pourzand, Mohammad Vojdanparast, Negar Morovatfar, Javad Ramezani, Ramin Khamene-Bagheri, Pouya Nezafati

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in ARYA atherosclerosis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Ali EshraghiAssistant Professor, Atherosclerosis Prevention Research Center AND Department of Cardiology, Imam Reza School of Medicine, Imam Reza Hospital, Mashhad, University of Medical Sciences, Mashhad, Iran.
Roya Naranji-SaniResident, Department of Cardiology, Imam Reza School of Medicine, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Hourak PourzandAssociate Professor, Atherosclerosis Prevention Research Center AND Department of Cardiology, Imam Reza School of Medicine, Imam Reza Hospital, Mashhad, University of Medical Sciences, Mashhad, Iran.
Mohammad VojdanparastCardiologist, Atherosclerosis Prevention Research Center, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Negar MorovatfarAssistant Professor, Imam Reza Clinical Research Units, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Javad RamezaniAssistant Professor, Atherosclerosis Prevention Research Center AND Department of Cardiology, Imam Reza School of Medicine, Imam Reza Hospital, Mashhad, University of Medical Sciences, Mashhad, Iran.
Ramin Khamene-BagheriAssistant Professor, Atherosclerosis Prevention Research Center AND Department of Cardiology, Imam Reza School of Medicine, Imam Reza Hospital, Mashhad, University of Medical Sciences, Mashhad, Iran.
Pouya NezafatiGeneral Practitioner, Cardiac Rehabilitation Research Center, Cardiovascular Research Institute, Isfahan University of Medicine Sciences, Isfahan, Iran.
Imam Reza Hospital · IRIsfahan University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundContrast-induced nephropathy (CIN) is a major concern following procedures with applying iodinated contrast media. The basis prevention of CIN is hydration and to avoid hypovolemia. We aimed to evaluate the efficacy of pentoxifylline (PTX) for the prevention of CIN in patients with myocardial infarction (MI) undergoing coronary angioplasty.

methodsThis prospective, single-blind, randomized clinical trial study was performed on 175 (127 men) of MI patients undergoing routine treatment. Patients were assigned randomly to the control (n = 84) and study groups (n = 91). In our study group, patients received 400 mg/3 times a day from 24 hours before to 24 hours after coronary angiography. In addition, before the procedure and after 48 hours from the procedure, serum creatinine was measured.

resultsCIN occurred in 14 patients (8.0%); 8 controls (9.5%) and 6 patients (6.6%) in the PTX group )P = 0.475) showing PTX to have no significant effect on CIN [P = 0.750, odds ratio = 0.82 (confidence interval = 0.24-2.8)] though a significantly different volume of contrast was used between the groups (231.29 ± 105.10 mm3 and 190.88 ± 75.82 mm3; P = 0.005, respectively).

conclusionThere was no significantly different occurrence of CIN on patients with MI, undergoing coronary angioplasty, but its relatively lower rate in PTX group would recommend the prophylactic oral use of PTX for CIN prevention.

Indexed as

AngioplastyContrast MediaCreatinineMyocardial InfarctionNephropathyPentoxifylline

Identifiers

PMID28458699
PMCPMC5403018
OpenAlexW2588569540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.